Endpoints News 25. März 2026 Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex
Endpoints News 25. März 2026 Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis' Scemblix
Endpoints News 24. März 2026 Karyopharm’s mixed myelofibrosis data; Rezolute to seek FDA approval despite trial failure
Endpoints News 24. März 2026 Q&A: Controversial embryo editing entrepreneur Cathy Tie on her new startup
Endpoints News 24. März 2026 Apnimed set to exit sleep disorder joint venture with Shionogi for $100M upfront
Endpoints News 24. März 2026 Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in
Endpoints News 24. März 2026 Merck partners with Flagship startup Quotient to search for genetic clues to IBD
Endpoints News 23. März 2026 Novartis to invest $480M in China following AstraZeneca and Lilly pledges
Endpoints News 23. März 2026 Former Acorda CEO Ron Cohen emerges at Parkinson’s cell therapy biotech Oryon